Temat: "Neoplasms" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Autorzy:: Chang H; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Marquez J; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Chen BK; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Kim DM; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Cheng ML; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Liu EV; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Yang H; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Zhang L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Sinha M; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Cheung A; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Kwek SS; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Chow ED; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Department of Biochemistry and Biophysics, Center for Advanced Technologies, University of California San Francisco, San Francisco, California.
Bridge M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Aggarwal RR; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Friedlander TW; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Small EJ; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Anderson M; Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, California.
Fong L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.; Pokaż więcej
Źródło:: Cancer immunology research [Cancer Immunol Res] 2024 Apr 02; Vol. 12 (4), pp. 453-461.
Typ publikacji:: Journal Article
MeSH Terms:: Bone Neoplasms*/drug therapy
Bone Neoplasms*/prevention & control
Bone Neoplasms*/secondary
Denosumab*/therapeutic use
Humans ; Male ; Kidney Neoplasms/drug therapy ; RANK Ligand/antagonists & inhibitors ; Prostatic Neoplasms/drug therapy

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Tytuł:: Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Autorzy:: Abu-Rustum NR; Memorial Sloan Kettering Cancer Center.
Yashar CM; UC San Diego Moores Cancer Center.
Arend R; O'Neal Comprehensive Cancer Center at UAB.
Barber E; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Bradley K; University of Wisconsin Carbone Cancer Center.
Brooks R; UC Davis Comprehensive Cancer Center.
Campos SM; Dana-Farber/Brigham and Women's Cancer Center.
Chino J; Duke Cancer Institute.
Chon HS; Moffitt Cancer Center.
Crispens MA; Vanderbilt-Ingram Cancer Center.
Damast S; Yale Cancer Center/Smilow Cancer Hospital.
Fisher CM; University of Colorado Cancer Center.
Frederick P; Roswell Park Comprehensive Cancer Center.
Gaffney DK; Huntsman Cancer Institute at the University of Utah.
Gaillard S; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Giuntoli R II; Abramson Cancer Center at the University of Pennsylvania.
Glaser S; City of Hope National Medical Center.
Holmes J; Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Howitt BE; Stanford Cancer Institute.
Kendra K; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
Lea J; UT Southwestern Simmons Comprehensive Cancer Center.
Lee N; The UChicago Medicine Comprehensive Cancer Center.
Mantia-Smaldone G; Fox Chase Cancer Center.
Mariani A; Mayo Clinic Comprehensive Cancer Center.
Mutch D; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
Nagel C; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
Nekhlyudov L; Dana-Farber/Brigham and Women's Cancer Center.
Podoll M; Vanderbilt-Ingram Cancer Center.
Rodabaugh K; Fred & Pamela Buffett Cancer Center.
Salani R; UCLA Jonsson Comprehensive Cancer Center.
Schorge J; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
Siedel J; University of Michigan Rogel Cancer Center.
Sisodia R; Mass General Cancer Center.
Soliman P; The University of Texas MD Anderson Cancer Center.
Ueda S; UCSF Helen Diller Family Comprehensive Cancer Center.
Urban R; Fred Hutchinson Cancer Center.
Wethington SL; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Wyse E; Patient Advocate.
Zanotti K; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
McMillian N; National Comprehensive Cancer Network.
Espinosa S; National Comprehensive Cancer Network.; Pokaż więcej
Źródło:: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Mar; Vol. 22 (2), pp. 117-135.
Typ publikacji:: Journal Article; Practice Guideline
MeSH Terms:: Vulvar Neoplasms*/diagnosis
Vulvar Neoplasms*/epidemiology
Vulvar Neoplasms*/etiology
Female ; Humans ; Adenocarcinoma/pathology ; Genital Neoplasms, Female ; Paget Disease, Extramammary/diagnosis ; Paget Disease, Extramammary/etiology ; Paget Disease, Extramammary/therapy ; Skin Neoplasms

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 3.

Tytuł:: Forget lung, breast or prostate cancer? Why we shouldn't abandon tumour names yet.
Autorzy:: Stenzinger A
Klauschen F; Pokaż więcej
Źródło:: Nature [Nature] 2024 Mar; Vol. 627 (8002), pp. 38.
Typ publikacji:: Letter
MeSH Terms:: Dissent and Disputes*
Neoplasms*/classification
Neoplasms*/diagnosis
Neoplasms*/drug therapy
Neoplasms*/genetics
Terminology as Topic*
Female ; Humans ; Male ; Breast Neoplasms ; Lung Neoplasms ; Prostatic Neoplasms

Opinia redakcyjna

na półce

Szczegóły

Skocz do pozycji: 4.

Tytuł:: Clinicopathological analysis of rosette-forming glioneuronal tumors.
Autorzy:: Liu J; Department of Pathology, Shenzhen Second People's Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen University School of Medicine, Shenzhen, 518035, China.
Lin F; Department of Radiology, Shenzhen Second People's Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen University School of Medicine, Shenzhen, 518035, China.
Sun Y; Department of Pathology, Shenzhen Second People's Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen University School of Medicine, Shenzhen, 518035, China.
Liu X; Department of Pathology, Shenzhen Second People's Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen University School of Medicine, Shenzhen, 518035, China. .; Pokaż więcej
Źródło:: Diagnostic pathology [Diagn Pathol] 2024 Feb 22; Vol. 19 (1), pp. 39. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:: Review; Journal Article
MeSH Terms:: Brain Neoplasms*/genetics
Brain Neoplasms*/pathology
Neoplasms, Neuroepithelial*/genetics
Neoplasms, Neuroepithelial*/pathology
Adult ; Female ; Humans ; Male ; Central Nervous System Neoplasms/genetics ; Central Nervous System Neoplasms/pathology ; Diagnosis, Differential ; Fourth Ventricle/pathology ; Mutation ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Exploring genetic associations of Crohn's disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations.
Autorzy:: Yu C; Jiangxi Medical College, Nanchang University, Nanchang, China.
Xu J; Jiangxi Medical College, Nanchang University, Nanchang, China.
Xu S; Jiangxi Medical College, Nanchang University, Nanchang, China.
Tang L; Jiangxi Medical College, Nanchang University, Nanchang, China.
Han Q; Jiangxi Medical College, Nanchang University, Nanchang, China.
Zeng X; Jiangxi Medical College, Nanchang University, Nanchang, China.
Huang Y; Jiangxi Medical College, Nanchang University, Nanchang, China.
Yu T; Department of breast surgery, Jiangxi Cancer Hospital, Nanchang, China.
Sun Z; Department of breast surgery, Jiangxi Cancer Hospital, Nanchang, China.; Pokaż więcej
Źródło:: Frontiers in immunology [Front Immunol] 2024 Feb 08; Vol. 15, pp. 1339207. Date of Electronic Publication: 2024 Feb 08 (Print Publication: 2024).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Colitis, Ulcerative*/epidemiology
Colitis, Ulcerative*/genetics
Crohn Disease*/epidemiology
Crohn Disease*/genetics
East Asian People*/genetics
East Asian People*/statistics & numerical data
European People*/genetics
European People*/statistics & numerical data
Neoplasms*/epidemiology
Neoplasms*/ethnology
Neoplasms*/genetics
Humans ; Breast Neoplasms ; Genetic Predisposition to Disease/ethnology ; Genetic Predisposition to Disease/genetics ; Genome-Wide Association Study ; Pancreatic Neoplasms ; Reproducibility of Results ; Risk Factors ; Uterine Cervical Neoplasms

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 6.

Tytuł:: Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer: A Meta-Analysis.
Autorzy:: Chi C; Department of Oncology, People's Hospital of Rizhao, Rizhao, Shandong, China.
Wang C; Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Dong L; Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Li X; Department of Pneumology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University.
Xu L; Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.; Pokaż więcej
Źródło:: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP [J Coll Physicians Surg Pak] 2024 Apr; Vol. 34 (4), pp. 461-467.
Typ publikacji:: Journal Article; Meta-Analysis
MeSH Terms:: Cranial Irradiation*/methods
Lung Neoplasms*/pathology
Lung Neoplasms*/radiotherapy
Small Cell Lung Carcinoma*/pathology
Small Cell Lung Carcinoma*/radiotherapy
Humans ; Brain Neoplasms/prevention & control ; Brain Neoplasms/secondary

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 7.

Tytuł:: Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
Autorzy:: Johnson N; Pokaż więcej
Źródło:: The Journal of clinical investigation [J Clin Invest] 2024 Apr 01; Vol. 134 (7). Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:: Journal Article; News
MeSH Terms:: MutL Protein Homolog 1*/genetics
MutL Protein Homolog 1*/metabolism
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Humans ; Adaptor Proteins, Signal Transducing/genetics ; Adaptor Proteins, Signal Transducing/metabolism ; BRCA2 Protein/genetics ; BRCA2 Protein/metabolism ; Genomic Instability ; MutS Homolog 2 Protein/genetics ; MutS Homolog 2 Protein/metabolism ; Neoplasms/genetics ; Neoplasms/metabolism ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 8.

Tytuł:: BRG1 mediates epigenetic regulation of TNFα-induced CCL2 expression in oral tongue squamous cell carcinoma cells.
Autorzy:: Xu M; School of Stomatology, Fujian Medical University, Fuzhou, China.; Department of Implantology, Stomatological Hospital of Xiamen Medical College & Xiamen Key Laboratory of Stomatological Disease Diagnosis and Treatment, Xiamen, Fujian, China.
Lu X; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Zhu F; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Sun X; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Yao H; Department of Implantology, Stomatological Hospital of Xiamen Medical College & Xiamen Key Laboratory of Stomatological Disease Diagnosis and Treatment, Xiamen, Fujian, China.
Zhang J; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Chen W; Department of Stomatology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, Zhejiang, China.
Zhu H; Department of Pathology, The 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi, China.
Liu F; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Shi SL; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Deng X; Department of Basic Medical Science, School of Medicine, Xiamen University, Xiamen, Fujian, China.; Pokaż więcej
Źródło:: Journal of cellular biochemistry [J Cell Biochem] 2024 Apr; Vol. 125 (4), pp. e30535. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Squamous Cell*/genetics
Head and Neck Neoplasms*
Tongue Neoplasms*/genetics
Tumor Necrosis Factor-alpha*/metabolism
Humans ; Chemokine CCL2/metabolism ; Epigenesis, Genetic ; Histones/metabolism ; Mouth Neoplasms ; NF-kappa B/metabolism ; Squamous Cell Carcinoma of Head and Neck ; Tumor Microenvironment

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 9.

Tytuł:: Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes.
Autorzy:: Wimberly CE; Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina.; Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina.
Gulrajani NB; Children's Health and Discovery Institute, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Russ JB; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Landi D; Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina.; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Wiemels JL; Center for Genetic Epidemiology, Norris Comprehensive Cancer Center, and Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California.
Towry L; Alex's Lemonade Stand Foundation, Bala Cynwyd, Pennsylvania.
Wiencke JK; Department of Neurological Surgery, University of California San Francisco, San Francisco, California.
Walsh KM; Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina.; Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina.; Children's Health and Discovery Institute, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina.; Pokaż więcej
Źródło:: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2024 Mar 01; Vol. 33 (3), pp. 347-354.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:: Illicit Drugs*/adverse effects
Tobacco Use*/adverse effects
Alcohol Drinking*/adverse effects
Neoplasms*/epidemiology
Prenatal Exposure Delayed Effects*
Child ; Female ; Humans ; Pregnancy ; Brain Neoplasms ; Cannabis ; Cerebellar Neoplasms ; Lymphoma, Non-Hodgkin ; Medulloblastoma ; Retinal Neoplasms ; Retinoblastoma ; Substance-Related Disorders/epidemiology

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 10.

Tytuł:: Ethnic disparities in cancer mortality in the capital and northeast of the State of São Paulo, Brazil 2001-17.
Autorzy:: Guimarães Ribeiro A; Cancer Surveillance Branch, International Agency for Research On Cancer, 25 Avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France. .; Educational and Research Institute, Barretos Cancer Hospital, Barretos, Brazil. .
Ferlay J; Cancer Surveillance Branch, International Agency for Research On Cancer, 25 Avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.
Vaccarella S; Cancer Surveillance Branch, International Agency for Research On Cancer, 25 Avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.
Dias de Oliveira Latorre MDR; School of Public Health, University of São Paulo, São Paulo, Brazil.
Tavares Guerreiro Fregnani JH; Educational and Research Institute, Barretos Cancer Hospital, Barretos, Brazil.; A. C. Camargo Cancer Center, São Paulo, Brazil.
Bray F; Cancer Surveillance Branch, International Agency for Research On Cancer, 25 Avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.; Pokaż więcej
Źródło:: Cancer causes & control : CCC [Cancer Causes Control] 2024 Mar; Vol. 35 (3), pp. 523-529. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Ethnicity*/statistics & numerical data
South American People*/statistics & numerical data
Neoplasms*/epidemiology
Neoplasms*/ethnology
Neoplasms*/mortality
Health Inequities*
Humans ; Brazil/epidemiology ; Cities/statistics & numerical data ; Lung Neoplasms/epidemiology ; Lung Neoplasms/ethnology ; Lung Neoplasms/mortality ; Healthcare Disparities/ethnology ; Healthcare Disparities/statistics & numerical data

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 11.

Tytuł:: Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: A population-based cross-sectional study.
Autorzy:: Mahar AL; Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada.; School of Nursing, Queen's University, Kingston, Ontario, Canada.; ICES, Ontario, Toronto, Canada.
Biggs K; ICES, Ontario, Toronto, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
Hansford RL; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
Derksen S; Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada.
Griffiths R; ICES, Ontario, Toronto, Canada.
Enns JE; Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada.
Dawe DE; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.; CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.
Hallet J; ICES, Ontario, Toronto, Canada.; Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Kristjanson M; CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.; St. Amant Research Centre, Winnipeg, Manitoba, Canada.; Department of Family Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Decker K; CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Cobigo V; ICES, Ontario, Toronto, Canada.; Department of Psychology, University of Ottawa, Ottawa, Ontario, Canada.
Shooshtari S; St. Amant Research Centre, Winnipeg, Manitoba, Canada.; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Stirling M; Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada.; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Kelly C; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Brownell M; Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Manitoba, Canada.; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Turner D; CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Ouellette-Kuntz H; ICES, Ontario, Toronto, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.; Pokaż więcej
Źródło:: Cancer [Cancer] 2024 Mar 01; Vol. 130 (5), pp. 740-749. Date of Electronic Publication: 2023 Oct 30.
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms:: Colorectal Neoplasms*/complications
Colorectal Neoplasms*/diagnosis
Colorectal Neoplasms*/epidemiology
Developmental Disabilities*
Lung Neoplasms*/complications
Lung Neoplasms*/diagnosis
Lung Neoplasms*/epidemiology
Adult ; Female ; Humans ; Cross-Sectional Studies ; Ontario/epidemiology ; Male ; Breast Neoplasms

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 12.

Tytuł:: Dietary patterns linked to lower odds of malnutrition are associated with all-cause and cancer mortality in adults with cancer.
Autorzy:: Curtis AR; Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia. Electronic address: .
Livingstone KM; Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia.
Daly RM; Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia.
Abbott G; Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia.
Kiss N; Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia; Allied Health Research, Peter MacCallum Cancer Centre, Melbourne, Australia.; Pokaż więcej
Źródło:: The journal of nutrition, health & aging [J Nutr Health Aging] 2024 Feb; Vol. 28 (2), pp. 100026. Date of Electronic Publication: 2024 Jan 01.
Typ publikacji:: Observational Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cancer Survivors*/statistics & numerical data
Dietary Patterns*
Malnutrition*/epidemiology
Malnutrition*/etiology
Neoplasms*/epidemiology
Neoplasms*/mortality
Aged ; Female ; Humans ; Male ; Middle Aged ; Biological Specimen Banks/statistics & numerical data ; Fatty Acids, Unsaturated ; Head and Neck Neoplasms/epidemiology ; Head and Neck Neoplasms/mortality ; Prognosis ; Prospective Studies ; Risk ; United Kingdom/epidemiology ; Vitamin D

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 13.

Tytuł:: Cancer mortality in Germany-born Americans and Germans.
Autorzy:: Mignozzi S; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Santucci C; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address: .
Medina HN; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Negri E; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
La Vecchia C; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Pinheiro PS; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.; Pokaż więcej
Źródło:: Cancer epidemiology [Cancer Epidemiol] 2024 Feb; Vol. 88, pp. 102519. Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: European People*
Neoplasms*/mortality
Female ; Humans ; Male ; Carcinoma, Renal Cell ; Colorectal Neoplasms ; Germany/epidemiology ; Kidney Neoplasms ; Lung Neoplasms ; United States/epidemiology

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 14.

Tytuł:: Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
Autorzy:: Zhao B; School and Hospital of Stomatology, Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of Oral Soft and Hard Tissues Restoration and Regeneration, Tianjin 300070, China.
Qin X; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China; Tianjin' s Clinical Research Center for Cancer, Tianjin 300060, China.
Fu R; School and Hospital of Stomatology, Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of Oral Soft and Hard Tissues Restoration and Regeneration, Tianjin 300070, China.
Yang M; College of Chemical Engineering, Inner Mongolia University of Technology, Hohhot 010051, China.
Hu X; School and Hospital of Stomatology, Tianjin Medical University, Tianjin 300070, China; Tianjin Key Laboratory of Oral Soft and Hard Tissues Restoration and Regeneration, Tianjin 300070, China.
Zhao S; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China; Tianjin' s Clinical Research Center for Cancer, Tianjin 300060, China.
Cui Y; Program in Gene Expression and Regulation, The Wistar Institute, Philadelphia, PA 19104, USA.
Guo Q; College of Chemical Engineering, Inner Mongolia University of Technology, Hohhot 010051, China. Electronic address: .
Zhou W; Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: .; Pokaż więcej
Źródło:: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Apr; Vol. 368, pp. 623-636. Date of Electronic Publication: 2024 Mar 16.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/metabolism
Carcinoma, Squamous Cell*/pathology
Cyclin-Dependent Kinase 4*/antagonists & inhibitors
Drug Resistance, Neoplasm*
Mouth Neoplasms*/drug therapy
Mouth Neoplasms*/metabolism
Mouth Neoplasms*/pathology
Nanoparticles*
Cyclin-Dependent Kinase 6*/antagonists & inhibitors
Animals ; Humans ; Mice ; Cell Line, Tumor ; Cell Proliferation ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Head and Neck Neoplasms/drug therapy ; Squamous Cell Carcinoma of Head and Neck/drug therapy

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 15.

Tytuł:: HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression.
Autorzy:: Shi Q; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Huang F; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Wang Y; Guangzhou National Laboratory , Guangzhou, China.
Liu H; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Deng H; MOE Key Laboratory of Bioinformatics, School of Life Sciences, Tsinghua University, Beijing, China.
Chen YG; The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.; Guangzhou National Laboratory , Guangzhou, China.; School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.; Pokaż więcej
Źródło:: The Journal of cell biology [J Cell Biol] 2024 Apr 01; Vol. 223 (4). Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Transforming Growth Factor beta*/metabolism
Receptor, ErbB-2*/chemistry
Receptor, ErbB-2*/genetics
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Animals ; Humans ; Mice ; Lung Neoplasms/secondary ; Mitogen-Activated Protein Kinases/metabolism ; Morphogenesis ; Phosphorylation ; Proto-Oncogene Proteins c-akt/metabolism ; Receptor, Transforming Growth Factor-beta Type I/metabolism ; Breast/growth & development

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 16.

Tytuł:: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Autorzy:: Powles T; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Valderrama BP; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Gupta S; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Bedke J; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Kikuchi E; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Hoffman-Censits J; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Iyer G; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Vulsteke C; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Park SH; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Shin SJ; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Castellano D; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Fornarini G; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Li JR; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Gümüş M; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Mar N; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Loriot Y; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Fléchon A; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Duran I; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Drakaki A; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Narayanan S; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Yu X; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Gorla S; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
Homet Moreno B; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).
van der Heijden MS; From Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, London (T.P.); Hospital Universitario Virgen del Rocio, Seville (B.P.V.), Hospital Universitario 12 de Octubre, Madrid (D.C.), and Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Santander (I.D.) - all in Spain; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (S. Gupta); Klinikum Stuttgart Katharinen Hospital, Stuttgart, Germany (J.B.); St. Marianna University School of Medicine, Kawasaki, Japan (E.K.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.); Memorial Sloan Kettering Cancer Center, New York (G.I.); Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, and the Center for Oncological Research, University of Antwerp, Antwerp - both in Belgium (C.V.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Severance Hospital, Yonsei University Health System (S.J.S.) - both in Seoul, South Korea; Scientific Institute for Research, Hospitalization, and Healthcare Ospedale Policlinico San Martino, Genoa, Italy (G.F.); Taichung Veterans General Hospital, Taichung, Taiwan (J.-R.L.); Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey (M.G.); the University of California, Irvine Medical Center, Orange (N.M.), and the University of California, Los Angeles Medical Center, Los Angeles (A.D.); Institut Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), and Centre Léon Bérard, Lyon (A.F.) - both in France; Seagen, Bothell, WA (S.N., X.Y.); Astellas Pharma US, Northbrook, IL (S. Gorla); Merck, Rahway, NJ (B.H.M.); and the Netherlands Cancer Institute, Amsterdam (M.S.H.).; Pokaż więcej
Corporate Authors:: EV-302 Trial Investigators
Źródło:: The New England journal of medicine [N Engl J Med] 2024 Mar 07; Vol. 390 (10), pp. 875-888.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal*/administration & dosage
Antibodies, Monoclonal*/adverse effects
Antibodies, Monoclonal*/therapeutic use
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Carcinoma, Transitional Cell*/secondary
Antineoplastic Agents*/administration & dosage
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/therapeutic use
Urologic Neoplasms*/drug therapy
Urologic Neoplasms*/pathology
Urologic Neoplasms*/secondary
Humans ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cisplatin/therapeutic use ; Urinary Bladder Neoplasms ; Gemcitabine/administration & dosage ; Gemcitabine/adverse effects ; Gemcitabine/therapeutic use ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carboplatin/therapeutic use ; Survival Analysis

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 17.

Tytuł:: The impact of LncRNA-SOX2-OT/let-7c-3p/SKP2 Axis on head and neck squamous cell carcinoma progression: Insights from bioinformatics analysis and experimental validation.
Autorzy:: Wang D; Department of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, People's Republic of China.
Zhao X; Department of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, People's Republic of China.
Li S; Department of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, People's Republic of China.
Guo H; Department of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, People's Republic of China.
Li S; Department of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, People's Republic of China.
Yu D; Department of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, People's Republic of China. Electronic address: .; Pokaż więcej
Źródło:: Cellular signalling [Cell Signal] 2024 Mar; Vol. 115, pp. 111018. Date of Electronic Publication: 2023 Dec 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Head and Neck Neoplasms*/genetics
Head and Neck Neoplasms*/pathology
MicroRNAs*/genetics
MicroRNAs*/metabolism
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Squamous Cell Carcinoma of Head and Neck*/genetics
Squamous Cell Carcinoma of Head and Neck*/secondary
Animals ; Humans ; Mice ; Computational Biology ; Gene Expression Regulation, Neoplastic ; Lung Neoplasms/secondary ; RNA, Messenger/metabolism ; SOXB1 Transcription Factors/genetics ; SOXB1 Transcription Factors/metabolism ; Tumor Microenvironment

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 18.

Tytuł:: YTHDF1's Regulatory Involvement in Breast Cancer Prognosis, Immunity, and the ceRNA Network.
Autorzy:: Luo W; Department of Pathophysiology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China.; Second Clinical Medical College, Nanchang University, Nanchang 330006, China.
Zhou Y; Department of Pathophysiology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China.
Wang J; First Clinical Medical College, Nanchang University, Nanchang 330006, China.
Wang K; First Clinical Medical College, Nanchang University, Nanchang 330006, China.
Lin Q; Department of Pathophysiology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China.
Li Y; Queen Mary School, Nanchang University, Nanchang 330006, China.
Xie Y; College of Pharmacy, Nanchang University, Nanchang 330006, China.
Li M; Second Clinical Medical College, Nanchang University, Nanchang 330006, China.
Wang J; Key Laboratory of Functional and Clinical Translational Medicine, Xiamen Medical College, Fujian Province University, Xiamen 361023, China.
Xiong L; Department of Pathophysiology, Medical College, Nanchang University, 461 Bayi Road, Nanchang 330006, China.; Key Laboratory of Functional and Clinical Translational Medicine, Xiamen Medical College, Fujian Province University, Xiamen 361023, China.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 04; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:: Journal Article
MeSH Terms:: MicroRNAs*/genetics
RNA-Binding Proteins*/genetics
Breast Neoplasms*/genetics
Breast Neoplasms*/immunology
Breast Neoplasms*/metabolism
Humans ; Blotting, Western ; Neoplasms ; RNA, Antisense ; RNA, Competitive Endogenous/genetics ; RNA, Competitive Endogenous/metabolism ; Tumor Microenvironment/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Autorzy:: Chen Y; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Agricultural Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Gao Z; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Agricultural Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Mohd-Ibrahim I; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, Agricultural Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Yang H; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Wu L; Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Fu Y; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Deng Y; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.; Pokaż więcej
Źródło:: Clinical and translational medicine [Clin Transl Med] 2024 Feb; Vol. 14 (2), pp. e1543.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Bromodomain Containing Proteins*
Transcription Factors*/genetics
Transcription Factors*/metabolism
Neoplasms*/diagnosis
Neoplasms*/genetics
Humans ; Chromatin ; Chromosomal Proteins, Non-Histone/genetics ; Colonic Neoplasms ; Melanoma/diagnosis ; Melanoma/drug therapy ; Melanoma/genetics ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Intraoperative electrochemotherapy of the posterior resection surface after pancreaticoduodenectomy: Preliminary results of a hybrid approach treatment of pancreatic cancer.
Autorzy:: Čebron Ž; University Medical Centre Ljubljana, Department of Abdominal Surgery, Zaloska 7, SI-1000 Ljubljana, Slovenia; University of Ljubljana, Medical Faculty, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Djokić M; University Medical Centre Ljubljana, Department of Abdominal Surgery, Zaloska 7, SI-1000 Ljubljana, Slovenia; University of Ljubljana, Medical Faculty, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Petrič M; University Medical Centre Ljubljana, Department of Abdominal Surgery, Zaloska 7, SI-1000 Ljubljana, Slovenia; University of Ljubljana, Medical Faculty, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Čemažar M; Institute of Oncology Ljubljana, Department of Experimental Oncology, Zaloska 2, SI-1000 Ljubljana, Slovenia; University of Primorska, Faculty of Health Sciences, Polje 42, SI-6310 Izola, Slovenia.
Bošnjak M; Institute of Oncology Ljubljana, Department of Experimental Oncology, Zaloska 2, SI-1000 Ljubljana, Slovenia.
Serša G; Institute of Oncology Ljubljana, Department of Experimental Oncology, Zaloska 2, SI-1000 Ljubljana, Slovenia; University of Ljubljana, Faculty of Health Sciences, Zdravstvena pot 5, SI-1000 Ljubljana, Slovenia. Electronic address: .
Trotovšek B; University Medical Centre Ljubljana, Department of Abdominal Surgery, Zaloska 7, SI-1000 Ljubljana, Slovenia; University of Ljubljana, Medical Faculty, Vrazov trg 2, 1000 Ljubljana, Slovenia. Electronic address: .; Pokaż więcej
Źródło:: Bioelectrochemistry (Amsterdam, Netherlands) [Bioelectrochemistry] 2024 Feb; Vol. 155, pp. 108576. Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:: Journal Article
MeSH Terms:: Electrochemotherapy*/methods
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/surgery
Adenocarcinoma*
Humans ; Pancreaticoduodenectomy/adverse effects ; Pancreaticoduodenectomy/methods ; Prospective Studies ; Pilot Projects ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Szczegóły

Informacja

Wyszukujesz frazę ""Neoplasms"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji